Isidro Cortes Ciriano
Research Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Year:
2026
Year:
2025
Complex de novo structural variants (dnSVs) are crucial genetic factors in rare disorders, yet their prevalence and characteristics in rare disorders remain poorly understood. Here, we conduct a comprehensive analysis of whole-genome sequencing data of 12,568 families, including 13,698 offspring with rare diseases, obtained as part of the UK 100,000 Genomes Project. We identify 1,870 dnSVs, constituting the largest dnSV dataset reported to date. Complex dnSVs (n = 158; 8.4%) emerge as the third most common type of SV, following simple deletions and duplications. We classify 65% of these complex dnSVs into 11 subtypes. Among probands with dnSVs (n = 1,696), 9% exhibit exon-disrupting pathogenic dnSVs associated with the probands’ phenotype. Notably, 12% of exon-disrupting pathogenic dnSVs and 22% of de novo deletions or duplications previously identified by array-based or whole-exome sequencing methods are found to be complex dnSVs. We also find distinct genomic properties of de novo deletions depending on the parent of origin. This study highlights the importance of complex dnSVs in the cause of rare disorders and demonstrates the necessity of specific genomic analysis to avoid overlooking these variants.
Year:
2025
Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.
Year:
2025
Somatic chromosome instability results in widespread structural and numerical chromosomal abnormalities (CAs) during cancer evolution 1–3 . Although CAs have been linked to mitotic errors resulting in the emergence of nuclear atypia 4–7 , the underlying processes and rates of spontaneous CA formation in human cells are underexplored. Here we introduce machine-learning-assisted genomics and imaging convergence (MAGIC)—an autonomously operated platform that integrates live-cell imaging of micronucleated cells, machine learning on-the-fly and single-cell genomics to systematically investigate CA formation. Applying MAGIC to near-diploid, non-transformed cell lines, we track de novo CAs over successive cell cycles, highlighting the common role of dicentric chromosomes as initiating events. We determine the baseline CA mutation rate, which approximately doubles in TP53 -deficient cells, and observe that chromosome losses arise more frequently than gains. The targeted induction of DNA double-strand breaks along chromosome arms triggers distinct CA processes, revealing stable isochromosomes, coordinated segregation and amplification of isoacentric segments in multiples of two, as well as complex CA outcomes, influenced by the chromosomal break location. Our data contrast de novo CA spectra from somatic mutational landscapes after selection occurred. The experimentation enabled by MAGIC advances the dissection of DNA rearrangement processes, shedding light on fundamental determinants of chromosomal instability.
Year:
2025
We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed and progressive solid tumors of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intratumor heterogeneity captured by the latter, if sufficient ctDNA was present. Serial tumor sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature. In keeping with epigenetic alterations being a common driver of many childhood cancers, fragmentomic analysis of cfDNA identified tumor-specific epigenetic states and transcription factor binding sites accessible in chromatin. This study leverages a large and well-annotated genomic dataset of aggressive childhood malignancies, identifies genomic and epigenetic drivers of childhood cancer relapse, and highlights the power and practicality of cfDNA analysis to capture both intratumoral heterogeneity and the epigenetic state of cancer cells. Significance: In tumors of childhood, we identify mutations in epigenetic genes as drivers of relapse, with matched cfDNA sequencing showing significant intratumor genetic heterogeneity and cell-state specific patterns of chromatin accessibility. This highlights the power of cfDNA analysis to identify both genetic and epigenetic drivers of aggressive disease in pediatric cancers.
Year:
2025
Year:
2024
Mitotic errors generate micronuclei entrapping mis-segregated chromosomes, which are susceptible to catastrophic fragmentation through chromothripsis. The reassembly of fragmented chromosomes by error-prone DNA double-strand break (DSB) repair generates diverse genomic rearrangements associated with human diseases. How specific repair pathways recognize and process these lesions remains poorly understood. Here we use CRISPR/Cas9 to systematically inactivate distinct DSB repair pathways and interrogate the rearrangement landscape of fragmented chromosomes. Deletion of canonical non-homologous end joining (NHEJ) components substantially reduces complex rearrangements and shifts the rearrangement landscape toward simple alterations without the characteristic patterns of chromothripsis. Following reincorporation into the nucleus, fragmented chromosomes localize within sub-nuclear micronuclei bodies (MN bodies) and undergo ligation by NHEJ within a single cell cycle. In the absence of NHEJ, chromosome fragments are rarely engaged by alternative end-joining or recombination-based mechanisms, resulting in delayed repair kinetics, persistent 53BP1-labeled MN bodies, and cell cycle arrest. Thus, we provide evidence supporting NHEJ as the exclusive DSB repair pathway generating complex rearrangements from mitotic errors.
Year:
2024
Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to end-to-end fusions, we find patterns of TFs that we mechanistically link to the activity of the alternative lengthening of telomeres (ALT) pathway. We show that TFs can be detected in the blood of cancer patients, which enables cancer detection with high specificity and sensitivity even for early-stage tumours and cancers of high unmet clinical need. Overall, we report a genomic footprint that enables characterization of the telomere maintenance mechanism of tumours and liquid biopsy analysis.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (67)
Raymond H. Kim
Associate Professor
University Health Network
Ruoyan Li
Assistant Professor
The University of Texas MD Anderson Cancer Center
Marlies Meisel
Assistant Professor (tenure track)
University of Pittsburgh
Jose Espejo Valle-Inclan
Principal Investigator
Champalimaud Foundation
Russell Taylor Sundby
Assistant Professor
Thomas Jefferson University
Elizabeth Christie
Peter MacCallum Cancer Institute
Sahand Hormoz
Dana-Farber Cancer Institute
Raheleh Rahbari
Group Leader
Wellcome Sanger Institute
Brendan C. Dickson
-
Michael Hubank
Professor of Translational Genomics
University College London
Juliet Gray
Professor of Paediatric Oncology
University of Southampton
Emanuel Gonçalves
Assistant Professor
Instituto de Engenharia de Sistemas e Computadores Tecnologia e Ciência
Matija Snuderl
Assistant Professor (Clinical) of Pathology
NYU School of Medicine
Peter Park
Harvard University
Adrienne M Flanagan
Professor of Musculoskeletal Pathology
-
Chris Jones
Professor of Childhood Brain Tumour Biology
Institute of Cancer Research
Justin Jordan
University of Texas Southwestern Medical Center
Steven C. Clifford
Prof of Molecular Paediatric Oncology
Newcastle University
Kathleen Burns
Professor and Department Chair
Dana-Farber Cancer Institute
Jihoon Kim
Assistant Professor
Yale University
Susanne Andrea Gatz
University of Birmingham
Jeffrey Szymanski
Assistant Professor
Mayo Clinic Minnesota
William Anderson
University College London
Guy Makin
Senior Lecturer in Paediatric Oncology
The University of Manchester
Trevor A Graham
Director
Institute of Cancer Research
Janet Shipley
Group Leader, Sarcoma Molecular Pathology
Institute of Cancer Research
David Viskochil
Professor
University of Utah
Deborah A. Tweddle
-
Joseph Christopher
University of Cambridge
Abel Gonzalez-Perez
Co-PI
IRB Barcelona
Ridwan Shaikh
Institute of Cancer Research
Pedro Beltrao
Associate Professor
ETH Zürich
Edward Curry
Imperial College London
Bissan Al-Lazikani
Professor, Director of Therapeutics Data Science
The University of Texas MD Anderson Cancer Center
Rita Cascão
Gulbenkian Institute for Molecular Medicine
Chong Chu
Principal Investigator
The Wistar Institute
Francisco Sanchez-Vega
Assistant Attending Computational Biologist
Memorial Sloan Kettering Cancer Center
Carlos Caldas
Professor
Hebrew University of Jerusalem
Angela C. Hirbe
Washington University School of Medicine
Sally George
Institute of Cancer Research
Matthew Hurles
Wellcome Sanger Institute
Anthony Davis
Assistant Professor
University of Texas Southwestern Medical Center
Nischalan Pillay
Professor
University College London
Maxime Tarabichi
Group Leader
Université libre de Bruxelles
Alicia L Bruzos
Junior Group Leader of Marine Transmissible Cancers Group
Max Planck Institute for Marine Microbiology
Peter Campbell
Wellcome Sanger Institute
Elsa Bernard
Group Leader
Institut Gustave Roussy
Richard Grundy
Professor of Paediatric Neuro-Oncology and Cancer Biology
University of Nottingham
Kevin Jones
Professor
University of Utah
Peter Ly
Assistant Professor
University of Texas Southwestern Medical Center
Ofer Shoshani
Assistant Prof
Weizmann Institute of Science
Louis Chesler
professor
Institute of Cancer Research
Claudia Faria
Invited Assistant Professor
Universidade do Porto Faculdade de Medicina
Marta Kovatcheva
Group Leader (Assistant Professor Equivalent)
IFOM – The AIRC Institute of Molecular Oncology
Amos Burke
Professor of Paediatric Oncology and Director
University of Birmingham
Nathan Reticker-Flynn
Assistant Professor
Stanford University
Andrea Sottoriva
Head
Human Technopole
Yoshihiro Nishida
Nagoya University Hospital
Peter Westcott
Assistant Professor
Massachusetts Institute of Technology
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Samantha Bersani
University of Verona
Marilyn Bui
Senior Member and Professor
H Lee Moffitt Cancer Center and Research Institute
Darren Hargrave
University College London
Anke Katharina Bergmann
Director, Chair
University Hospital Würzburg
Carolin Sauer
Group Leader
Vall d'Hebron Institute of Oncology
Pamela Kearns
University of Birmingham
Aylwyn Scally
Group leader
University of Cambridge
Make your next move.
Prepare your application
Review drafts before you send them.